

Specimen ID: 268-059-0949-0
 Control ID: 41249429399

Acct # [REDACTED]

Phone: (813) 445-7342 Rte: 00

Defy Medical, LLC
 4809 N Armenia Ave Ste 220
 Tampa FL 33603


Patient Details

DOB: 05/13/1964
 Age(y/m/d): 056/04/11
 Gender: M
 Patient ID:

Specimen Details

Date collected: 09/24/2020 0752 Local
 Date received: 09/24/2020
 Date entered: 09/24/2020
 Date reported: 10/03/2020 0707 ET

Physician Details

Ordering: [REDACTED]
 Referring:
 ID:
 NPI: 1093940041

General Comments & Additional Information

Total Volume: Not Provided

Fasting: Yes

Ordered Items

CBC With Differential/Platelet; Comp. Metabolic Panel (14); Lipid Panel; Testosterone, Free and Total; Dihydrotestosterone; DHEA, Serum; TSH; Prostate-Specific Ag, Serum; IGF-1; Estradiol, Sensitive; Sex Horm Binding Glob, Serum; Non LCA Req; Handwritten Order; Blood Drawing; Cardiovascular Report

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	5.9		x10E3/uL	3.4-10.8	01
RBC	5.49		x10E6/uL	4.14-5.80	01
Hemoglobin	17.7		g/dL	13.0-17.7	01
Hematocrit	52.0	High	%	37.5-51.0	01
MCV	95		fL	79-97	01
MCH	32.2		pg	26.6-33.0	01
MCHC	34.0		g/dL	31.5-35.7	01
RDW	12.8		%	11.6-15.4	01
Platelets	166		x10E3/uL	150-450	01
Neutrophils	56		%	Not Estab.	01
Lymphs	27		%	Not Estab.	01
Monocytes	11		%	Not Estab.	01
Eos	5		%	Not Estab.	01
Basos	1		%	Not Estab.	01
Neutrophils (Absolute)	3.3		x10E3/uL	1.4-7.0	01
Lymphs (Absolute)	1.6		x10E3/uL	0.7-3.1	01
Monocytes (Absolute)	0.7		x10E3/uL	0.1-0.9	01
Eos (Absolute)	0.3		x10E3/uL	0.0-0.4	01
Baso (Absolute)	0.1		x10E3/uL	0.0-0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uL	0.0-0.1	01
Comp. Metabolic Panel (14)					
Glucose	97		mg/dL	65-99	01
BUN	13		mg/dL	6-24	01
Creatinine	0.88		mg/dL	0.76-1.27	01
eGFR If NonAfricn Am	96		mL/min/1.73	>59	
eGFR If Africn Am	111		mL/min/1.73	>59	

Patient: ~~██████████~~
 DOB: 05/13/1964

Patient ID:

 Control ID: ~~██████████~~

 Specimen ID: 268-059-0949-0
 Date collected: 09/24/2020 0752 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
BUN/Creatinine Ratio	15			9-20	
Sodium	139				
Potassium	4.7		mmol/L	134-144	01
Chloride	102		mmol/L	3.5-5.2	01
Carbon Dioxide, Total	25		mmol/L	96-106	01
Calcium	9.7		mg/dL	20-29	01
Protein, Total	6.7		g/dL	8.7-10.2	01
Albumin	4.5		g/dL	6.0-8.5	01
Globulin, Total	2.2		g/dL	3.8-4.9	01
A/G Ratio	2.0			1.5-4.5	
Bilirubin, Total	0.9		mg/dL	1.2-2.2	
Alkaline Phosphatase	60		IU/L	0.0-1.2	01
AST (SGOT)	41	High	IU/L	39-117	01
ALT (SGPT)	85	High	IU/L	0-40	01
				0-44	01
Lipid Panel					
Cholesterol, Total	97	Low	mg/dL	100-199	01
Triglycerides	116		mg/dL	0-149	01
HDL Cholesterol	45		mg/dL	>39	01
VLDL Cholesterol Cal	21		mg/dL	5-40	
LDL Chol Calc (NIH)	31		mg/dL	0-99	
Testosterone, Free and Total					
Testosterone, Serum	747		ng/dL	264-916	01
Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103.					
Free Testosterone(Direct)	26.8	High	pg/mL	7.2-24.0	02
Dihydrotestosterone					
	66		ng/dL		03
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Reference Range: Adult Male: 30 - 85					
DHEA, Serum					
Dehydroepiandrosterone (DHEA) ^A	147		ng/dL	31-701	02
			Age		
			1 - 5 years	0 - 67	
			6 - 7 years	0 - 110	
			8 - 10 years	0 - 185	
			11 - 12 years	0 - 201	
			13 - 14 years	0 - 318	
			15 - 16 years	39 - 481	
			17 - 19 years	40 - 491	

Patient: [REDACTED]
 DOB: [REDACTED]

Patient ID:

Control [REDACTED]

 Specimen ID: 268-059-0949-0
 Date collected: 09/24/2020 0752 Local

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
			>19 years	31 - 701	
TSH	1.530		uIU/mL	0.450-4.500	01
Prostate-Specific Ag, Serum					
Prostate Specific Ag, Serum	2.1		ng/mL	0.0-4.0	01
Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.					
IGF-1					
Insulin-Like Growth Factor I	112		ng/mL	68-247	02
Estradiol, Sensitive					
	19.2		pg/mL	8.0-35.0	02
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared by the Food and Drug Administration. Methodology: Liquid chromatography tandem mass spectrometry (LC/MS/MS)					
Sex Horm Binding Glob, Serum	13.1	Low	nmol/L	19.3-76.4	01
Cardiovascular Report					
Interpretation	Note				04
Medical Director's Note: Test(s) 004102-Dehydroepiandrosterone (DHEA) was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. Supplemental report is available.					
PDF					04
Comments:					
A This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.					

01	MB	LabCorp Birmingham 1801 First Avenue South, Birmingham, AL 35233-1935	Dir: Brian Ragland, MD
02	BN	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: Sanjai Nagendra, MD
03	ES	Esoterix Inc 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358	Dir: Samuel Pepkowitz, MD
04	LITIL	Litholink Corporation 150 Spring Lake Dr Ste A, Itasca, IL 60143-2091	Dir: John Asplin, MD

For inquiries, the physician may contact Branch: 800-877-5227 Lab: 205-581-3500